IOB - Delayed Quote CHF

Idorsia Ltd (0RQE.IL)

Compare
0.7725
-0.0215
(-2.71%)
At close: January 10 at 4:12:50 PM GMT
Currency in CHF All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
74,122.0000
152,386.0000
97,102.0000
35,349.0000
71,758.0000
Cost of Revenue
16,520.0000
7,150.0000
6,266.0000
--
--
Gross Profit
57,602.0000
145,236.0000
90,836.0000
35,349.0000
--
Operating Expense
451,004.0000
688,290.0000
893,800.0000
648,353.0000
482,341.0000
Operating Income
-393,402.0000
-543,054.0000
-802,964.0000
-613,004.0000
-410,583.0000
Net Non Operating Interest Income Expense
-30,322.0000
-39,107.0000
-17,124.0000
-21,802.0000
-38,697.0000
Pretax Income
-295,436.0000
-294,253.0000
-820,089.0000
-634,805.0000
-449,279.0000
Tax Provision
992.0000
3,668.0000
7,807.0000
-210.0000
-4,160.0000
Net Income Common Stockholders
-296,428.0000
-297,921.0000
-827,896.0000
-634,595.0000
-444,791.0000
Diluted NI Available to Com Stockholders
-296,428.0000
-297,921.0000
-827,896.0000
-634,595.0000
-444,791.0000
Basic EPS
-1.65
-1.67
-4.67
-3.77
-3.11
Diluted EPS
-1.65
-1.67
-4.67
-3.77
-3.11
Basic Average Shares
179,951.6220
178,246.8720
177,433.9340
168,498.0480
142,809.0720
Diluted Average Shares
179,951.6220
178,246.8720
177,433.9340
168,498.0480
142,809.0720
Total Operating Income as Reported
-265,113.0000
-255,145.0000
-802,965.0000
-613,004.0000
-410,582.0000
Total Expenses
467,524.0000
695,440.0000
900,066.0000
648,353.0000
482,341.0000
Net Income from Continuing & Discontinued Operation
-296,428.0000
-297,921.0000
-827,896.0000
-634,595.0000
-444,791.0000
Normalized Income
-413,811.5200
-561,355.9050
-827,896.0000
-634,595.0000
-444,791.0000
Interest Expense
19,459.0000
20,668.0000
17,172.0000
27,937.0000
9,717.0000
Net Interest Income
-30,322.0000
-39,107.0000
-17,124.0000
-21,802.0000
-38,697.0000
EBIT
-275,977.0000
-273,585.0000
-802,917.0000
-606,868.0000
-439,562.0000
EBITDA
-258,350.0000
-254,551.0000
-783,088.0000
-588,835.0000
-420,637.0000
Reconciled Cost of Revenue
16,520.0000
7,150.0000
6,266.0000
--
--
Reconciled Depreciation
17,627.0000
19,034.0000
19,829.0000
18,033.0000
18,925.0000
Net Income from Continuing Operation Net Minority Interest
-296,428.0000
-297,921.0000
-827,896.0000
-634,595.0000
-444,791.0000
Total Unusual Items Excluding Goodwill
128,288.0000
287,907.0000
--
--
--
Total Unusual Items
128,288.0000
287,907.0000
--
--
--
Normalized EBITDA
-386,638.0000
-542,458.0000
-783,088.0000
-588,835.0000
-420,637.0000
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0000
0.0000
Tax Effect of Unusual Items
10,904.4800
24,472.0950
--
--
--
12/31/2020 - 6/16/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DB0.F Q32 Bio Inc.
3.0000
+0.67%
 
OPTI.L OptiBiotix Health Plc
17.50
0.00%
 
5CV.MU CureVac NV
4.0800
+3.82%
 
RLF.SW Relief Therapeutics Holding SA
3.8500
-1.53%
 
SNG.L Synairgen plc
2.0875
-6.49%
 
LXEO Lexeo Therapeutics, Inc.
6.39
-6.30%
 
CLGN CollPlant Biotechnologies Ltd.
4.1983
-5.87%
 
ZBIO Zenas BioPharma, Inc.
8.12
-12.50%
 
PLUR Pluri Inc.
4.2400
-2.30%
 
GLSI Greenwich LifeSciences, Inc.
12.38
-7.27%